About Stelexis Therapeutics
Stelexis is a cancer therapeutics company, utilizing its proprietary platform to selectively target pre-cancerous stem cells to discover and develop therapies. Its proprietary drug discovery platform identifies the earliest definable pre-cancerous stem and progenitor cells that lead to the formation of human primary and recurrent tumors for therapeutic intervention and relapse prevention.
Latest Stelexis Therapeutics News
Jan 14, 2019
Venture roundup: Apic, Stelexis, Biond, Keros 9:41 AM PDF Gene therapy company Apic Bio Inc. (Cambridge, Mass.) and cancer company Stelexis Therapeutics LLC (New York, N.Y.) each announced series A rounds of at least $40 million. Other companies that announced venture rounds include Biond Biologics Ltd. (Misgav Industrial Park, Israel), which raised $17 million in a series B round, and Keros Therapeutics Inc. (Lexington, Mass. ), which raised a $23 million series B round. Apic plans to use its $40 million series A to develop APB-101, a "liver sparing" gene therapy treatment... Read the full 387 word article User Sign in
Stelexis Therapeutics Frequently Asked Questions (FAQ)
When was Stelexis Therapeutics founded?
Stelexis Therapeutics was founded in 2017.
Where is Stelexis Therapeutics's headquarters?
Stelexis Therapeutics's headquarters is located at 780 Third Avenue, New York.
What is Stelexis Therapeutics's latest funding round?
Stelexis Therapeutics's latest funding round is Series A.
How much did Stelexis Therapeutics raise?
Stelexis Therapeutics raised a total of $43M.